Teleflex Incorporated (TFX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2,537 | 2,810 | 2,791 | 2,974 | 3,047 | 1,993 | 2,601 | 2,268 |
| Operating profit | $m | 256 | 87 | ||||||
| Net profit | $m | 335 | 485 | 363 | 356 | 70 | -906 | -1,029 | 330 |
| EPS reported | $ | -20.25 | -23.29 | ||||||
| Operating cashflow per share | $ | 7.63 | 9.24 | ||||||
| Capex per share | $ | 2.13 | 0.27 | ||||||
| FCF per share | $ | 5.50 | 8.97 | ||||||
| Free cash flow | $m | 245 | 391 | ||||||
| Net debt | $m | 2,248 | 2,508 | ||||||
| Book value equity | $m | 3,125 | 2,905 | ||||||
| Book value per share | $ | 69.87 | 66.53 | ||||||
| Number of shares | m | 44.72 | 43.66 | ||||||
| DPS (TTM paid) | $ | 1.36 | 1.36 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.74 | 1.87 | ||||||
| P/S LTM | x | 2.73 | 2.09 | ||||||
| P/FCF LTM | x | 22.19 | 13.94 | ||||||
| EV/EBITDA LTM | x | 25.71 | -32.67 | ||||||
| EV/Sales LTM | x | 3.90 | 3.28 | ||||||
| Earnings Yield LTM | % | -16.63% | -17.58% | ||||||
| FCF Yield | % | +4.51% | +7.17% | ||||||
| Quality | |||||||||
| ROE | % | -28.98% | -31.83% | ||||||
| ROIC | % | +4.07% | +1.30% | ||||||
| Operating margin | % | +12.84% | +3.35% | ||||||
| Gross margin | % | +56.24% | +53.77% | ||||||
| FCF/Sales | % | +12.32% | +15.02% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -34.61% | -14.66% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | -51.81% | -23.30% | ||||||
| Operating Profit Growth | % | +69.39% | -42.34% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +1.11% | +1.01% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | -6.65% | -5.83% | ||||||
| FCF/Debt | x | 0.09 | 0.14 | ||||||
| Net Debt/EBITDA | x | 7.71 | -10.81 | ||||||
| EBIT/Net interest | x | 2.55 | 0.73 | ||||||
| Net debt/market cap | % | +48.51% | +47.21% | ||||||
| Net debt/Equity | x | 0.72 | 0.86 | ||||||
| Gross debt/equity | x | 0.87 | 0.99 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free